UV-induced N-ras mutations are T-cell targets in human melanoma

Melanoma Research

Volumn 7, Issue SUPPL. 2, 1997, Pages

  Van Elsas, Andrea ^a   Scheibenbogen, Carmen ^b   Van der Minne, Carolien ^a   Zerp, Shuraila F ^a   Keilholz, Ulrich ^b   Schrier, Peter I ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Carcinogenesis; Cytotoxic T lymphocytes; Immunotherapy; Melanoma; Oncogene; Peptide; Ras; UV radiation

Indexed keywords

ARTICLE; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; ONCOGENE N RAS; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; SKIN CARCINOGENESIS; T LYMPHOCYTE; ULTRAVIOLET RADIATION;

EID: 0030779785     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199708001-00017     Document Type: Article

References (57)

1. Marchand M, Weynants P, Rankin E., et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-885.
2. Jaeger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo. implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66:162-169.
3. Boon T, Cerottini J, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337-365.
4. Cells E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994; 91:2105-2109.
5. Visseren MJW, Van Elsas A, Van der Voort EIH, et al. Cytotoxic T-lymphocytes specific for the tyrosinase autoantigen can be induced from healty donor blood to lyse melanoma cells. J Immunol 1995; 154:3991-3998.
6. Van Elsas A, Van der Burg SH, Van der Minne CE, et al. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol 1996; 26:1683-1689.
7. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch Dermatol 1995; 131:164-169.
8. Elwood JM, Gallagher RP. Sun exposure and epidemiology of melanoma. In Epidemiological Aspects of Melanoma. Edited by Gallagher RP, Elwood JM. Boston: Kluwer, 1994:15-66.
9. Holman CD, Armstrong BK, Heenan PJ. A theory of the etiology and pathogenesis ot human cutaneous malignant melanoma. J Natl Cancer Inst 1983; 71:651-656.
10. Monach PA, Meredith SC, Siegel CT, et al. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995; 2:45-59.
11. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320:1367-1372.
12. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome-9p13-p22. Science 1992; 258:1148-1152.
13. Kamb A, Shattuck-Eidens D, Ecles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8:22-26.
14. INK1 in human cancer. Proc Natl Acad Sci USA 1994; 91:11045-11049.
15. INK1b genes, as well as neighbouring markers, in sporadic melanoma. Cancer Rev 1996; 56:5023-5032.
16. Hussussain CJ, Struewing JP, Goldstein AM, et al. Gemline p16 mutations in familial melanoma. Nat Genet 1994; 8:15-21.
17. Grruis NA, Van der Velden PA, Sandkuijl LA, et al. Homozygotes for CDKN2 (p16) germline mutations in Dutch familial melanoma kindreds. Nat Genet 1995; 10:351-353.
18. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:70-1-707.
19. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 1995; 375:503-506.
20. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475-5483.
21. INK1a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281-1284.
22. INKla binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12:97-99.
23. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A 1993; 90:4216-4220.
24. Hartmann A, Blaszyk H, Cunningham JS, et al. Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer 1996; 67:313-317.
25. Pollock PM, Yu F, Qiu I., et al. Evidence for UV induction of CDKN2 mutations in melanoma cell lines. Oncogene 1995; 11:663-668.
26. Versteeg R, Noordermeer IA, Krüse-Wolters KM, et al. c-myc downregulates class I HLA expression in human melanomas. EMBO J 1988; 7:1023-1029.
27. Van Elsas A, Zerp S, Van der Flier S, et al. Relevance of UV-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996; 149:883-893.
28. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:1682-4689.
29. GAP and neuro-fibromatosis product activities. Nature 1991; 351:576-579.
30. Bollag G, McCormick F. Regulators and effectors of ras proteins. Annu Rev Cell Biol 1991; 7:601-632.
31. Van't Veer LJ, Bungering BMT, Versteeg R, et al. N-ras mutations in human cutaneous melanoma on sun-exposed body sites. Mol Cell Biol 1989; 9:3114-3116.
32. Albino AP, Sozzi G, Nanus DM, et al. Malignant transformation of human melanocytes: induction of a complete melanoma phonotype and genotype. Oncogene 1992; 7:2315-2321.
33. Ball NJ, Yohn JJ, Morelli JG, et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102:285-290.
34. Pierceall WE, Ananthaswamy HN. Transformation of NIH-3T3 cells by transfection with UN-irradiated human c-Ha-ras-1 proto-oncogene DNA. Oncogene 1991; 6:2085-2091.
35. Nishigori C, Wang S, Miyakoshi J, et al. Mutations in ms genes in cells cultured from mouse skin tumors induced by ultraviolet irradiation. Proc Natl Acad Sci U S A 1994; 91:7189-7193.
36. Melicf CJM, Kast WM. Potential immunogenicity of oncogene and tumor suppressor gene products. Curr Opin Immunol 1993; 5:709-713.
37. Houbiers JGA, Nijman HW, Van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993; 23:2072-2077.
38. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357-1365.
39. Yanuck M, Carbone DP, Pendleton D, et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993; 53:3257-3261.
40. Dahl AM, Beverley PCL, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol 1996; 157:239-246.
41. Fisk BT, Blevins L, Wharton JT, et al. Identification ol an immunodominant peptide of Her-2/neu protooncogene recognized by ovarian tumor specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181:2109-2120.
42. Peoples GE, Goedegebuure PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same Her-2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92:432-436.
43. BCR ABI protein. Proc Natl Acad Sci U S A 1992; 89:1468-1472.
44. Jung S, Schluesener HJ. Human lymphocytes-T recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991; 173:273-276.
45. Peace DJ, Chen W, Nelson Nelson H, et al. T-cell recognition ot transforming proteins encoded by mutated ras proto-oncogenes. J Immunol 1991; 146:2059-2065.
46. Skipper J, Stauss HJ. Identification of 2 cytotoxic T-lymphocyte recognized epitopes in the ras protein. J Exp Med 1993; 177:1493-1498.
47. Fenton RG, Taub DD, Kwak LW, et al. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 1993; 85:1294-1302.
48. Gedde-Dahl T, Fossum B, Eriksen JA, et al. T-cell clones specific for p21 ras-detived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol 1993; 23;754-760.
49. Van Elsas A, Nijman HW, Van der Minne CF, et al. Induction and characterization ot cytotoxic T-lymphocytes recognizing mutated p21ras peptide presented by HLA-A*0201. Int J Cancer 1995: 61:389-396.
50. Ruppert J, Grey HM, Sette A, et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74:929-937.
51. Nijman HW, Houbiers JGA, Vierboom MPM, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur Immunol 1993; 23:115-1219.
52. Fossum B, Gedde-Dahl III T, Breivik J, et al. p21-ras-peptide specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-Asp). Int J Cancer 1994; 56:40-45.
53. Gedde-Dahl III T, Spurkland A, Eriksen JA, et al. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-Leu61). Int Immunol 1992; 4:1331-1337.
54. Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol 1992; 10:617-644.
55. Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1996; 83:1603-1611.
56. Keilholz U, Scheibenbogen C, Tilgen W, et al. Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 1993; 72:607-611.
57. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding Martl or gp100 for cancer therapy. J Immunol 1996; 156:700-710.